Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.19701 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von H Bachelez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, AP-HP Hôpital St. Louis, Paris, France. Hauptthemen laut MEDLINE: Piperidines, Pyrimidines, Arthritis, Psoriatic, Psoriasis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studiesDear Editor, Approximately 30% of patients with psoriasis have psoriatic arthritis (PsA). 1 Patients with PsA with joint/skin symptoms have worse disease activity/patient-reported outcomes (PROs) than patients with only joint symptoms.2 Tofacitinib is an oral Janus kinase inhibitor for treatment of PsA.Using pooled data from two global/52-week/Phase III studies, OPT Pivotal 1 and 2 [NCT01276639/NCT01309737], 3 this post hoc analysis examined the efficacy/PROs/safety of tofacitinib in patients with moderate to severe plaque psoriasis and history of PsA, and explored the role of itch/joint pain/morning stiffness in reducing depressive symptoms.In OPT Pivotal 1 and 2, patients were randomized to tofacitinib 5 or 10 mg twice daily (BID) or placebo.At Week 16, placebotreated patients were re-randomized to tofacitinib 5 or 10 mg BID to Week 52.Efficacy outcomes, to Week 52, included proportions of patients achieving Psoriasis Area and Severity Index (PASI)75, PASI90, and those with Itch Severity Item (ISI) score improvement from baseline >2 and Hospital Anxiety and Depression Scale Depression (HADS-D) subscale score 2, and change from baseline in ISI/JPA/morning stiffness were greater with tofacitinib 5 and 10 mg BID versus placebo (Figure 1a-f).Altogether, 45.2% and 46.5% of patients receiving tofacitinib 5 and 10 mg BID, respectively, had a HADS-D subscale score
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, AP-HP Hôpital St. Louis, Paris, France.
- Unité INSERM U1163, Imagine Institute, Université de Paris, Paris, France.
- Dermatology Centre, Salford Royal Hospital, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, UK.
- Department of Dermatology, King's College Hospital, King's College London, London, UK.
- Probity Medical Research and Alliance Clinical Trials Inc, Waterloo, Ontario, Canada.
- University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: C E M Griffiths, K A Papp, J F Merola, S R Feldman
Förderung
- Pfizer
Zitieren
APA
Bachelez, H., Griffiths, C. E. M., Papp, K. A., Hall, S., Merola, J. F., Feldman, S. R., Khraishi, M., Tan, H., Fallon, L., Cappelleri, J. C., Bushmakin, A. G., & Young, P. (2024). Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19701
Vancouver
Bachelez H, Griffiths CEM, Papp KA, Hall S, Merola JF, Feldman SR, et al. Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19701
BibTeX
@article{Bachelez2024,
author = {Bachelez, H and Griffiths, C E M and Papp, K A and Hall, S and Merola, J F and Feldman, S R and Khraishi, M and Tan, H and Fallon, L and Cappelleri, J C and Bushmakin, A G and Young, P},
title = {Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.19701}
}
EUVIMED